GlassScriptPhysician profile
Rawan Hani Jumean
NPI 1184715435
$8,829.35
in general payments reported to CMS, 2019-2025
37 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,556 · 2020: $493 · 2021: $1,236 · 2022: $1,764 · 2023: $1,569 · 2024: $1,099 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,756 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,756.33 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,028.29 | 2019-2025 | |
| Janssen Biotech, INC. | $956.87 | 2019-2024 | Tremfya, Simponi, Remicade |
| Lilly USA, LLC | $760.65 | 2019-2024 | Taltz |
| Amgen INC. | $715.28 | 2019-2025 | Evenity, Enbrel, Otezla |
| Impulse Dynamics (USA) INC. | $687.21 | 2021-2024 | Optimizer, Optimizer |
| Radius Health, INC. | $596.37 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $549.39 | 2019-2025 | Benlysta |
| Abbvie INC. | $436.98 | 2024-2025 | |
| Ucb, INC. | $380.27 | 2019-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $276.90 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $242.47 | 2021-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $189.01 | 2020-2023 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $185.94 | 2019-2021 | |
| Horizon Therapeutics Plc | $170.84 | 2020-2023 | Krystexxa |
| Abbott Laboratories | $163.76 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $143.53 | 2019-2024 | |
| Medtronic Vascular, INC. | $131.63 | 2019 | |
| Janssen Pharmaceuticals, INC | $128.57 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $116.01 | 2021-2023 | Strensiq |
| Sanofi-Aventis U.S. LLC | $110.58 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $110.02 | 2021-2022 | |
| Sobi, INC | $105.41 | 2021-2023 | |
| Medtronic, INC. | $101.84 | 2021-2023 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Biotronik INC. | $96.55 | 2021 | |
| Alvogen INC | $76.82 | 2024-2025 | Teriparatide |
| Kiniksa Pharmaceuticals International, Plc | $74.19 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.00 | 2023-2025 | Ofev |
| Genentech USA, INC. | $47.78 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $34.14 | 2025 | Purified Cortrophin Gel |
| Celgene Corporation | $32.67 | 2019 | |
| Medexus Pharma, INC. | $28.91 | 2019 | |
| Celltrion USA INC. | $25.00 | 2023 | Yuflyma |
| Kowa Pharmaceuticals America, INC. | $18.50 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.90 | 2021 | |
| Ibsa Pharma INC. | $16.07 | 2023 | Tirosint, Licart |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rawan Jumean listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.